Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8447291 | 0.86 | CA1 (0.58) | CNR2MAPTHPGDRAB9AKMT2A | |
| SCHEMBL27980232 | 0.85 | CNR2 (0.48) | CNR2RORCF2F10PLG | |
| SCHEMBL27625366 | 0.85 | PARP10 (0.50) | CNR2RORCF2F10PLG | |
| SCHEMBL6279399 | 0.84 | CNR2 (0.58) | CNR2RORCF2F10PLG | |
| SCHEMBL4115523 | 0.82 | CNR2 (0.53) | CNR2RORCHPGDKMT2ACYP3A4 | |
| SCHEMBL24172235 | 0.82 | GSK3B (0.51) | CNR2RORCF2F10PLG | |
| SCHEMBL28471067 | 0.82 | EPHX2 (0.40) | EPHX2NR1H4MAPTHPGDRAB9A | |
| SCHEMBL12003891 | 0.81 | MAOB (0.47) | MAPTHPGDRAB9AKMT2AMAOB | |
| SCHEMBL9211 | 0.81 | ALDH1A1 (0.49) | CNR2RORCMAPTHPGDKMT2A | |
| SCHEMBL8434856 | 0.81 | RORC (0.53) | CNR2RORCF2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227983-A1 | PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | AMR TECHNOLOGY, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-7390906-B2 | Forming ketone intermediates to terfenadine carboxylic acid metabolite; by use of pure regioisomer of 4-(Cyclopropyl-oxo-methyl)-alpha,alpha-dimethylphenylacetic acid | AMR TECHNOLOGY, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7238834-B2 | Piperidine derivatives and process for their production | AMR TECHNOLOGY, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| CN-1596240-A | Chalcone derivatives and their use for the treatment of diseases | ATHEROGENICS INC (US) | 2005-03-16 | — | — | CN | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | CNR2 2596/4885RORC 154/4885F2 2440/4885 |
| US-20080227983-A1 | PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | HRH4, DRD4, H1-4 | CNR2 343/4885RORC 3062/4885F2 2467/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | CNR2 2516/4885RORC 224/4885F2 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.